A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer

Mutations in TP53 lead to a defective G1 checkpoint and the dependence on checkpoint kinase 1 (Chk1) for G2 or S phase arrest in response to DNA damage. In preclinical studies, Chk1 inhibition resulted in enhanced cytotoxicity of several chemotherapeutic agents. The high frequency of TP53 mutations...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Cynthia X., Ellis, Matthew J. C., Petroni, Gina R., Guo, Zhanfang, Cai, Shi-rong, Ryan, Christine E., Craig Lockhart, A., Naughton, Michael J., Pluard, Timothy J., Brenin, Christiana M., Picus, Joel, Creekmore, Allison N., Mwandoro, Tibu, Yarde, Erin R., Reed, Jerry, Ebbert, Mark, Bernard, Philip S., Watson, Mark, Doyle, Laurence A., Dancey, Janet, Piwnica-Worms, Helen, Fracasso, Paula M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539064/
https://www.ncbi.nlm.nih.gov/pubmed/23242585
http://dx.doi.org/10.1007/s10549-012-2378-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539064/
https://www.ncbi.nlm.nih.gov/pubmed/23242585
http://dx.doi.org/10.1007/s10549-012-2378-9

Ejemplares similares